New combo therapy aims to halt lung cancer growth in advanced disease
Disease control
Recruiting now
This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive treatment every 21 days for up to 2 years, with r…
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC